Memantine LEK
Pays: Union européenne
Langue: bulgare
Source: EMA (European Medicines Agency)
Notice patient
(PIL)
16-11-2020
Résumé des caractéristiques du produit
(SPC)
16-11-2020
Rapport public d'évaluation
(PAR)
29-04-2013
Ingrédients actifs:
мемантин хидрохлорид
Disponible depuis:
Pharmathen S.A.
Code ATC:
N06DX01
DCI (Dénomination commune internationale):
memantine
Groupe thérapeutique:
Psychoanaleptics и други анти-деменция лекарства
Domaine thérapeutique:
Болест на Алцхаймер
indications thérapeutiques:
Лечение на пациенти с умерена до тежка болест на Алцхаймер.
Descriptif du produit:
Revision: 5
Statut de autorisation:
упълномощен
Date de l'autorisation:
2013-04-21
Notice patient
Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on +31 (0)88 781 7600.
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call +31 (0)65 008 9457 outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]
Lire le document complet
Résumé des caractéristiques du produit
Skip to main content [European Medicines Agency]
Menu *
EMA WEBSITE TEMPORARILY UNAVAILABLE
This website is currently unavailable due to essential maintenance.
EMERGENCY CONTACT DETAILS
To report a potentially serious problem with a centrally authorised
medicine, call our product emergency hotline on +31 (0)88 781 7600.
To report a product quality defect, including a suspected defect, of a
centrally authorised medicine that could result in a recall or
abnormal restriction on supply, marketing or manufacturing
authorisation holders can call +31 (0)65 008 9457 outside business
hours.
The details of your call may be documented, including personal data if
you provide them (such as your name, contact details and nature of the
issue raised), in accordance with our privacy statement. You can
consult our privacy statement at
https://www.ema.europa.eu/en/about-us/legal/general-privacy-statement
[/en/about-us/legal/general-privacy-statement] once the website is
back online.
RSS feed Twitter YouTube LinkedIn
© 1995-2020 European Medicines Agency
European Union agencies network [European Union agencies network]
An agency of the European Union [European Union flag]
Lire le document complet
